Mao R, Hou X, Feng X, Wang R, Fei X, Zhao J
Front Pharmacol. 2024; 15:1434625.
PMID: 39135787
PMC: 11317380.
DOI: 10.3389/fphar.2024.1434625.
Fu W, Kuang Y
Front Med (Lausanne). 2023; 10:1113840.
PMID: 37144035
PMC: 10151707.
DOI: 10.3389/fmed.2023.1113840.
Di Segni N, Busnelli A, Secchi M, Cirillo F, Levi-Setti P
Front Endocrinol (Lausanne). 2022; 13:907249.
PMID: 35979440
PMC: 9377693.
DOI: 10.3389/fendo.2022.907249.
Wang M, Huang R, Liang X, Mao Y, Shi W, Li Q
Reprod Biol Endocrinol. 2022; 20(1):114.
PMID: 35941630
PMC: 9358814.
DOI: 10.1186/s12958-022-00985-4.
Setti A, Braga D, Iaconelli Junior A, Borges Junior E
Rev Bras Ginecol Obstet. 2021; 43(10):749-758.
PMID: 34784631
PMC: 10183840.
DOI: 10.1055/s-0041-1736306.
Type and dose of gonadotropins in poor ovarian responders: does it matter?.
Boudry L, Racca A, Tournaye H, Blockeel C
Ther Adv Reprod Health. 2021; 15:26334941211024203.
PMID: 34263173
PMC: 8243085.
DOI: 10.1177/26334941211024203.
Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
Conforti A, Esteves S, Humaidan P, Longobardi S, DHooghe T, Orvieto R
Reprod Biol Endocrinol. 2021; 19(1):91.
PMID: 34154604
PMC: 8215738.
DOI: 10.1186/s12958-021-00759-4.
Correlation between luteinizing hormone receptor gene expression in human granulosa cells with oocyte quality in poor responder patients undergoing fertilization: A cross-sectional study.
Wiweko B, Satria M, Mutia K, Ameilia Iffanolida P, Harzif A, Pratama G
F1000Res. 2019; 8:16.
PMID: 31131092
PMC: 6530604.
DOI: 10.12688/f1000research.17036.1.
The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis.
Conforti A, Esteves S, Di Rella F, Strina I, De Rosa P, Fiorenza A
Reprod Biol Endocrinol. 2019; 17(1):18.
PMID: 30728019
PMC: 6366097.
DOI: 10.1186/s12958-019-0460-4.
Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A....
Santi D, Casarini L, Alviggi C, Simoni M
Front Endocrinol (Lausanne). 2017; 8:114.
PMID: 28620352
PMC: 5451514.
DOI: 10.3389/fendo.2017.00114.
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Mochtar M, Danhof N, Ayeleke R, van der Veen F, van Wely M
Cochrane Database Syst Rev. 2017; 5:CD005070.
PMID: 28537052
PMC: 6481753.
DOI: 10.1002/14651858.CD005070.pub3.
Comparison of FSH and hMG on ovarian stimulation outcome with a GnRH antagonist protocol in younger and advanced reproductive age women.
Tabata C, Fujiwara T, Sugawa M, Noma M, Onoue H, Kusumi M
Reprod Med Biol. 2015; 14:5-9.
PMID: 25620883
PMC: 4300428.
DOI: 10.1007/s12522-014-0186-0.
Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.
Lehert P, Kolibianakis E, Venetis C, Schertz J, Saunders H, Arriagada P
Reprod Biol Endocrinol. 2014; 12:17.
PMID: 24555766
PMC: 4015269.
DOI: 10.1186/1477-7827-12-17.
Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol.
Rabati B, Nasiri Zeidi S
J Res Med Sci. 2013; 17(11):1063-6.
PMID: 23833582
PMC: 3702089.
Early initiation of gonadotropin-releasing hormone antagonist in polycystic ovarian syndrome patients undergoing assisted reproduction: randomized controlled trial ISRCTN69937179.
Abuzeid M, Mitwally M, Abuzeid Y, Bokhari H, Ashraf M, Diamond M
J Assist Reprod Genet. 2012; 29(11):1193-202.
PMID: 22960769
PMC: 3510369.
DOI: 10.1007/s10815-012-9850-7.
GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).
Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F
Reprod Biol Endocrinol. 2012; 10:26.
PMID: 22500852
PMC: 3442989.
DOI: 10.1186/1477-7827-10-26.
Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF.
Spencer J, Browne A, Copland S, Session D
Reprod Biol Endocrinol. 2010; 8:29.
PMID: 20331901
PMC: 2855615.
DOI: 10.1186/1477-7827-8-29.
A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
Devroey P, Boostanfar R, Koper N, Mannaerts B, Ijzerman-Boon P, Fauser B
Hum Reprod. 2009; 24(12):3063-72.
PMID: 19684043
PMC: 2777786.
DOI: 10.1093/humrep/dep291.
Human choriogonadotropin prior to controlled ovarian stimulation and in vitro fertilization improves implantation, and pregnancy rates.
Motta E, Smith G, Serafini P, Coslovsky M, Hassun P, Rocha A
J Assist Reprod Genet. 2009; 26(6):305-11.
PMID: 19533324
PMC: 2729860.
DOI: 10.1007/s10815-009-9322-x.
Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes.
Detti L, Ambler D, Yelian F, Kruger M, Diamond M, E Puscheck E
J Assist Reprod Genet. 2008; 25(5):177-81.
PMID: 18461435
PMC: 2582065.
DOI: 10.1007/s10815-008-9217-2.
